Mainz Biomed (NASDAQ:QUCY) Issues Quarterly Earnings Results

by · The Cerbat Gem

Mainz Biomed (NASDAQ:QUCY – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.21) earnings per share (EPS) for the quarter, Zacks reports.

Mainz Biomed Trading Up 15.3%

Shares of QUCY traded up $0.46 during mid-day trading on Friday, hitting $3.46. The company’s stock had a trading volume of 81,650,607 shares, compared to its average volume of 41,098,360. The company has a 50-day moving average price of $0.63. Mainz Biomed has a 52-week low of $0.30 and a 52-week high of $4.93. The company has a market cap of $43.30 million, a price-to-earnings ratio of -0.05 and a beta of 0.42. The company has a quick ratio of 0.44, a current ratio of 0.50 and a debt-to-equity ratio of 1.55.

Mainz Biomed News Summary

Here are the key news stories impacting Mainz Biomed this week:

  • Positive Sentiment: The company launched quantum-cyber.ai, a new web platform aimed at homeland security, autonomous drones, counter-UAS, EMP shielding, autonomous demining, and quantum technology applications, giving investors a clearer story around its pivot into defense-related markets. Article Title
  • Positive Sentiment: A second release highlighted the same platform launch and emphasized the company’s “AI-powered, quantum-accelerated” autonomous defense positioning, which may be fueling speculative interest in the stock. Article Title
  • Positive Sentiment: The company announced that former Trump administration VA Secretary Peter O’Rourke Sr. joined its board, adding a politically connected defense/government figure that could improve credibility with investors. Article Title
  • Positive Sentiment: One report said the stock “rockets” on an exclusive drone technology licensing agreement, suggesting traders are reacting to a potentially meaningful commercialization catalyst. Article Title
  • Neutral Sentiment: Shares were repeatedly halted for LULD pauses, indicating extreme intraday volatility and heavy trading interest rather than a standalone fundamental update.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings raised shares of Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday. Maxim Group cut shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Mainz Biomed has an average rating of “Reduce”.

View Our Latest Stock Analysis on QUCY

Mainz Biomed Company Profile

(Get Free Report)

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

See Also